ADAR1 Capital Management LLC Sells 60,606 Shares of iBio, Inc. (NYSE:IBIO)

ADAR1 Capital Management LLC lessened its stake in shares of iBio, Inc. (NYSE:IBIO) by 12.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 415,606 shares of the company’s stock after selling 60,606 shares during the quarter. ADAR1 Capital Management LLC owned approximately 4.23% of iBio worth $1,018,000 as of its most recent SEC filing.

Separately, Geode Capital Management LLC grew its position in iBio by 52.3% in the 4th quarter. Geode Capital Management LLC now owns 83,797 shares of the company’s stock worth $205,000 after purchasing an additional 28,775 shares in the last quarter. 7.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of iBio to a “sell” rating in a report on Tuesday, March 18th.

iBio Trading Down 15.3 %

iBio stock opened at $3.22 on Monday. The firm’s 50 day moving average price is $4.21 and its 200-day moving average price is $3.13. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.05. iBio, Inc. has a 1 year low of $1.50 and a 1 year high of $6.89.

Insiders Place Their Bets

In other news, Director David Arkowitz purchased 18,382 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was acquired at an average price of $2.72 per share, with a total value of $49,999.04. Following the purchase, the director now directly owns 18,382 shares in the company, valued at approximately $49,999.04. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.58% of the company’s stock.

iBio Company Profile

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.